Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?-Reference-Cited by-同舟云学术

Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?

Published:2015-09-10 Issue:32 Volume:6 Page:33944-33951
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Iurlo Alessandra¹²,Orsi Emanuela³,Cattaneo Daniele¹,Resi Veronica³,Bucelli Cristina¹,Orofino Nicola¹,Sciumè Mariarita¹,Elena Chiara⁴,Grancini Valeria³,Consonni Dario⁵,Orlandi Ester Maria⁴,Cortelezzi Agostino¹

Affiliation:

1. Oncohematology Division, IRCCS Ca’ Granda - Maggiore Policlinico Hospital Foundation, and University of Milan, Milan, Italy

2. Oncohematology Unit of the Elderly, IRCCS Ca’ Granda - Maggiore Policlinico Hospital Foundation, and University of Milan, Milan, Italy

3. Endocrinology and Diabetes Unit, Department of Medical Sciences, IRCCS Ca’ Granda - Maggiore Policlinico Hospital Foundation, and University of Milan, Milan, Italy

4. Oncology-Hematology Department, Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

5. Epidemiology Unit, Department of Preventive Medicine, IRCCS Ca’ Granda - Maggiore Policlinico Hospital Foundation, Milan, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review;Frontiers in Pharmacology;2024-02-01

2. Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia;Internal Medicine;2024

3. Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper;ESMO Open;2023-12

4. Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies;Current Treatment Options in Oncology;2023-12

5. The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia;Hemato;2023-07-14